Skip Navigation



Annals of Oncology Advance Access published online on February 7, 2005
Annals of Oncology, doi:10.1093/annonc/mdi107
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/4/618    most recent
mdi107v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ganti, A. K.
Right arrow Articles by Armitage, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganti, A. K.
Right arrow Articles by Armitage, J. O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received November 4, 2004
Accepted November 9, 2004

Original article

Hematopoietic stem cell transplantation in mantle cell lymphoma

A. K. Ganti 1, P. J. Bierman 1, J. C. Lynch 2, R. G. Bociek 1, J. M. Vose 1, and J. O. Armitage 1*

1 Department of Internal Medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE, USA
2 Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

* To whom correspondence should be addressed.
J. O. Armitage, E-mail: joarmita{at}unmc.edu


  Abstract

Background: Patients with mantle cell lymphoma (MCL) have in general, lower response rates and overall survival (OS) than those with other B-cell non-Hodgkin's lymphomas. The role of hematopoietic stem cell transplantation (HSCT) in MCL is unclear. Hence we decided to study the clinical course of patients who received autologous and allogeneic HSCT for MCL.

Methods: Ninety-seven patients, (80 patients-autologous; 17 patients-allogeneic) who received a HSCT for mantle cell lymphoma were included in the study.

Results: The complete response rates at day 100 between the two groups were similar (73% vs. 62%). Day-100 mortality was higher in the allogeneic HSCT group (19% vs. 0%) (P < 0.01). The estimated 5-year relapse rates, 5-year event-free survival (EFS) and 5-year OS among the allogeneic HSCT patients were 21%, 44% and 49%, respectively, similar to 56%, 39% and 47% in the autologous group. Ten patients received HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone + high-dose methotrexate and cytarabine) ± rituximab prior to transplant. There have been no relapses or deaths amongst these patients at a median follow-up of 16 months.

Conclusions: Patients treated with allogeneic HSCT had a lower relapse rate, but similar EFS and OS to autologous HSCT. Treatment of MCL with HyperCVAD ± rituximab followed by HSCT seems promising.

Keywords: mantle cell lymphoma; autologous hematopoietic stem cell transplantation; allogeneic hematopoietic stem cell transplantation; HyperCVAD.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. Martin, A. Chadburn, P. Christos, K. Weil, R. R. Furman, J. Ruan, R. Elstrom, R. Niesvizky, S. Ely, M. DiLiberto, et al.
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
J. Clin. Oncol., March 10, 2009; 27(8): 1209 - 1213.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Martin, A. Chadburn, P. Christos, R. Furman, J. Ruan, M. A. Joyce, E. Fusco, P. Glynn, R. Elstrom, R. Niesvizky, et al.
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
Ann. Onc., July 1, 2008; 19(7): 1327 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba, A. D. Ho, N. Schmitz, and C. Pott
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Haematologica, January 1, 2007; 92(1): 42 - 49.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.